Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line rilvegostomig combinations versus atezolizumab + bevacizumab in advanced hepatocellular carcinoma
NL-OMON60666Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of rilvegostomig in hepatocellular carcinoma (HCC), sponsored by AstraZeneca. Primary endpoint: Overall survival. Started Mar 2026; status: recruiting.
02
Drugs
rilvegostomig
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NL-OMON60666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60666.